Type 2 diabetes mellitus in those who are18 years and above.
Mode of action
Brands containing this Ingredient
Drug Index 2.0 is hereOur new update features a more powerful search feature and easier login.
issues? Contact us
today. Contact Us
Mode of Action
It is a dipeptidyl peptidase-4 [DPP-4] inhibitor that acts by inhibition of the inactivation of GLP-1 and GIP by DPP-4, allowing GLP-1 and GIP to potentiate the secretion of insulin in the beta cells and suppress glucagon release by the alpha cells of the islets of Langerhans in the pancreas
General precautions: Reduce the dose of other hypoglycemic in case of concurrent use.
Precaution in hepatic diseases: Avoid in severe hepatic impairment.
Precautions in renal diseases: Dose adjustment not required in mild renal impairment. Reduce dose to 2.5mg OD in moderate or severe renal impairment. Avoid in end-stage renal disease requiring hemodialysis.
Allergy to saxagliptin or other dipeptidyl peptidase-4 [DPP4] inhibitors or any other ingredient of the formulation; type 1 diabetes mellitus; diabetic ketoacidosis.
Acute pancreatitis [like other DPP4 inhibitors]; URTI; UTI; headache; sinusitis; allergic reactions; hypoglycaemia; nausea and vomiting.
Special Information: Data not available for those below 18 yrs.